The Pulmonary Hypertension Association (PHA) provides this tool to help participants learn more about research ongoing in PH. Use the filters below to narrow the search results to fit your personal needs. Each listing describes current research, who qualifies to participate, and whom to contact for information.
No personal information can be collected through this tool. The information presented on the PHA Clinical Trials page has been obtained directly from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH). PHA recommends that you use the information in this resource to begin a conversation with your PH specialist about whether or not participating in research is right for you.
Due to radiation exposure and low but real risk of morbidity and mortality associated with
right heart catheterization, non-invasive procedures to estimate mPAP are desired for the
diagnosis of PH or to monitor treatment effectiveness. Echocardiography is used as a
screening tool to estimate systolic pulmonary arterial pressure (sPAP), but due various
limitations, this technique is not considered to be sufficiently accurate for the diagnosis
of PH. The aim of 4D flow MRI is to evaluate the complete time-varying tridirectional
velocity field in a volume of interest. It enables flow and velocity measurements in a
vascular region of...
This is a prospective, longitudinal, observational study of free-living activity trackers and
patient reported outcomes to test the hypothesis that daily activity will have stronger
prognostic value than 6MWD in patients with pulmonary hypertension after 12 weeks.
This study is a prospective, non-randomized, two arm, single-center acute feasibility study
assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH
In this prospective study, the investigators will implement a systematic assessment of
adherence to diuretics in a cohort of patients with precapillary pulmonary hypertension.
This study is designed to:
- determine the overall adherence rates for diuretic regimen
- determine the determinants of non-adherence to diuretics
- assess the risk of PH worsening occurrence in the non-adhesion group
The investigators intend to evalute the value of radiomics signature of pulmonary vessels
from chest computed tomography (CT) for dianosis and prognosis of pulmonary arterial
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored
trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these
trials until lack of patient benefit as assessed by investigator, or commercial availability
This study is being conducted to assess the long-term safety, tolerability, and efficacy of
sotatercept in participants with Pulmonary Arterial Hypertension (PAH). This open-label,
long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2,
NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional
improvements in the study participants, including those receiving maximal PAH therapy with
double/triple drug combinations and intravenous prostacyclin.
The primary objective of this open-label, LTFU study is to evaluate the long-term safety and
tolerability of sotatercept when added...
The aim of this study was to try to reduce the required dose of etomidate used in anesthesia
for upper endoscopy and colonoscopy in critically ill cardiac patients who complain of severe
anemia in cardiac intensive care units by using a low dose of ketamine, which helps to reduce
the side effects of etomidate, the most important of which is its suppressive effect on the
adrenal gland and the secretion of cortisol in such critical cases, while maintaining
hemodynamic stability, and the patient's satisfaction.
This single-arm, Phase 3, 2-part, open-label, multicenter study aims to demonstrate the
safety and tolerability of L606 in patients with PAH switching from a stable Tyvaso dose. The
study will determine the short-term and long-term safety and tolerability of L606 in this
patient population; also evaluate the steady-state pharmacokinetics (PK) of L606 as compared
to Tyvaso, effects on exercise ability, quality of life, and treatment satisfaction with L606
in patients with PAH.
Arrhythmias are considered a prominent phenomenon in pulmonary hypertension (PH) as the
disease progresses. According primarily to retrospective studies with up to 24 hours of
monitoring, supraventricular tachycardias (SVT) can be found in 8-35% of patients, with
significant impact on survival.
Furthermore, a few prospective studies to date deploying short-term monitoring (10 minutes-24
hours) have revealed lower heart rate variability (HRV) in patients with pulmonary arterial
In ASPIRE arrhythmias and heart rate variability is being assessed via long term monitoring.